BioSpace News Archive

Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab TELLOMAK Phase II clinical trial, evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas.

In a recent report by Transparency Market Research, the vendor landscape for global pulmonary arterial hypertension market is highly opportunistic.

Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy.

The competitive landscape of the global collagen market is extremely fragmented in nature.

As per a recent report by Transparency Market Research pertaining to global breast cancer therapeutics market states that the market is projected to grow substantially in from 2016 to 2024.

Rising investment in healthcare robotics is leading to growth in Robotic Nurse Assistant Market and this is further fuelled by rise in geriatric population worldwide.

Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.

Senzime AB announces that the company has initiated its Sales Ramp Up in the US to establish a direct sales force in key territories and that the company has signed distribution agreements for the Midwest and Northwest territories.

Avivagen Inc. a life sciences corporation focused on developing and commercializing immune-system improving products for livestock, companion animal and human applications, is pleased to announce that it has received approval from The Ministry of Agriculture-Feed Additives Division for the immediate use of OxC-beta™ Livestock in poultry, swine and cattle in Brazil.

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia.